Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor ...
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations. Safety and tolerability findings included: No serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results